The United Leukodystrophy Foundation (ULF) is proud and excited to announce a partnership with Marc Nolan, a Chicago-based footwear brand, who is launching a new
The U.S. Food and Drug Administration (FDA) has approved Koselugo (selumetinib), an oral MEK inhibitor developed by Alexion, AstraZeneca Rare Disease, for adults with neurofibromatosis
Hundreds more patients in England with relapsed or refractory diffuse large B-cell lymphoma (DLBCL) will gain earlier access to glofitamab (Columvi) after new guidance from
Vera Therapeutics has taken a major step toward transforming treatment for immunoglobulin A nephropathy (IgAN), submitting a Biologics License Application to the U.S. Food and
My journey started abruptly last year. It was a completely normal day—until it wasn’t. I’m an RN, and I slept most of the day before
I’m Jenna, a 36-year-old married mother of one son, and I have neuroendocrine cancer (NETs). It is a rare type of cancer, and 60% of
The FDA has granted full approval to Rubraca (rucaparib) for the treatment of BRCA-Mutated metastatic castration-resistant prostate cancer (mCRPC). Read more here:
patientworthy.com/2026/01/07/fda-grants-full-approval-to-rucaparib-for-brca-mutated-mcrpc/
Patient Worthy is looking for individuals who are interested in sharing their experiences with Diffuse Large B-Cell Lymphoma (DLBCL). Be the reason someone feels seen, supported, and inspired! If you're interested in learning more or joining the conversation this week, visit patientworthy.com for the latest information. If you have a story to share, click here: bit.ly/4dV7gru #DLBCL #shareyourstory #PatientWorthy
Insights Wanted: HER2+ mBC
© Copyright 2024 Patient Worthy
Sign Up With a Patient Worthy Account and Share Your Rare Story
- OR -
Make a difference, share your experiences and get paid. Opt-in and join Patient Worthy's panel for paid opportunities such as surveys, market research, patient advisory panels and more.
- OR -
Make a difference, share your experiences and get paid. Opt-in and join Patient Worthy's panel for paid opportunities such as surveys, market research, patient advisory panels and more.
